A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation

Journal of Nuclear Medicine

Volumn 43, Issue 11, 2002, Pages 1482-1488

  Robbins, Richard J ^a   Larson, Steven M ^a   Sinha, Naina ^a   Shaha, Ashok ^a   Divgi, Chaitanya ^a   Pentlow, Keith S ^a   Ghossein, Ronald ^a   Michael Tuttle, R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Radioactive iodine; Recombinant human thyrotropin; Thyroid neoplasms

Indexed keywords

IODINE 131; RECOMBINANT THYROTROPIN;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOIODINE REMNANT ABLATION; RADIOSURGERY; THYROID CARCINOMA; THYROIDECTOMY;

ADULT; CARCINOMA, PAPILLARY; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; THYROXINE;

EID: 0036841049     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Degroot LJ, Reilly M. Comparison of 30- and 50-mCi doses of iodine-131 for thyroid ablation. Ann Intern Med. 1982;96:51-53.
2. 131I ablation for papillary and follicular thyroid carcinoma. Thyroid. 1997;7:265-271.
3. Maxon HR, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer: A quantitative radiation dosimetric approach -outcome and validation in 85 patients. J Nucl Med. 1992;33:1132-1136.
4. 131Iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay. Radiother Oncol. 1998;47:325-330.
5. Lin JD, Kao PF, Chao TC. The effects of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma. Br J Radiol. 1998;71:307-313.
6. Muratet J, Daver A, Minier J, Larra F. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med. 1998;39:1546-1550.
7. 131I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer. 1996;77:2574-2580.
8. 131I-scanned and non-scanned individuals. J Clin Endocrinol Metab. 2001;86:3507-3511.
9. 131I in patients with differentiated thyroid carcinoma. Nucl Med Commun. 2001;22:1021-1027.
10. Tsang RW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK, Sutcliffe SB. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer. 1998;82:375-388.
11. Hundahl S, Fleming I, Fremgen A, Menck H. A national cancer database report on 53,856 cases of thyroid carcinoma treated in the US: 1985-1995. Cancer. 1998;83:2638-2648.
12. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447-1463.
13. Spencer C, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: Prevalence, influence on serum thyroglobulin measurements and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1998;83:1121-1127.
14. Hay ID. Papillary thyroid carcinoma. Endocrinol Metab Clin North Am. 1990; 19:545-576.
15. Sweeney DC, Johnston GS. Radioiodine therapy for thyroid cancer. Endocrinol Metab Clin North Am. 1995;24:803-839.
16. Ladenson P, Braverman L, Mazzaferri E, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med. 1997:337:888-896.
17. Haugen B. Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84:3877-3885.
18. Robbins RJ, Tuttle RM, Sharaf RN, et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2001;86: 619-625.
19. Robbins RJ, Tuttle RM, Sonenberg M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid. 2001; 11:865-869.
20. Benua R, Cicale N, Sonenberg M, Rawson R. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR. 1962;87:171-179.
21. 131I therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma. J Clin Endocrinol Metab. 1973;36: 1143-1152.
22. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71: 414-424.
23. Adler M, Macapinlac H, Robbins R. Radioiodine treatment of thyroid cancer with the aid of recombinant human thyrotropin. Endocr Pract. 1998;4:282-286.
24. Robbins RJ, Voelker E, Wang W, Macapinlac HA, Larson SM. Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: Case report and review of literature. Endocr Pract. 2000;6:460-464.
25. Roos D, Smith J. Randomized trials on radioactive iodine ablation of thyroid remnants for thyroid carcinoma. Int J Radiat Oncol Biol Phys. 1999;44:493-495.
26. Vermiglio F, Violi M, Finocchiaro M, et al. Short-term effectiveness of low-dose radioiodine ablative treatment of thyroid remnants after thyroidectomy for differentiated thyroid cancer. Thyroid. 1999;9:387-391.
27. 131I scintigraphy. Nucl Med Commun. 2000;21:529-532.
28. 131I dose in differentiated thyroid cancer. Clin Endocrinol (Oxf). 2000;52:765-773.